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Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are clinical tests commonly used to screen for coagulation-
factor deficiencies. One genome-wide association study (GWAS) has been reported previously for aPTT, but no GWAS has been reported
for PT. We conducted a GWAS and meta-analysis to identify genetic loci for aPTT and PT. The GWAS for aPTT was conducted in 9,240
individuals of European ancestry from the Atherosclerosis Risk in Communities (ARIC) study, and the GWAS for PT was conducted in
2,583 participants from the Genetic Study of Three Population Microisolates in South Tyrol (MICROS) and the Lothian Birth Cohorts
(LBC) of 1921 and 1936. Replication was assessed in 1,041 to 3,467 individuals. For aPTT, previously reported associations with KNG1,
HRG, F11, F12, and ABO were confirmed. A second independent association in ABO was identified and replicated (rs8176704, p ¼
4.26 3 1024). Pooling the ARIC and replication data yielded two additional loci in F5 (rs6028, p ¼ 3.22 3 109) and AGBL1
(rs2469184, p ¼ 3.61 3 108). For PT, significant associations were identified and confirmed in F7 (rs561241, p ¼ 3.71 3 1056) and
PROCR/EDEM2 (rs2295888, p ¼ 5.25 3 1013). Assessment of existing gene expression and coronary artery disease (CAD) databases
identified associations of five of the GWAS loci with altered gene expression and two with CAD. In summary, eight genetic loci that
account for ~29% of the variance in aPTT and two loci that account for ~14% of the variance in PT were detected and supported by
functional data.Activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT) are clinical tests commonly used to
screen for coagulation-factor deficiencies.1–3 aPTTmeasures
the clotting time between the activation of factor XII (FXII)
and the formation of a fibrin clot; thus, aPTT reflects the
integrity of the intrinsic and common coagulation path-
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common coagulation pathways.2,3 Shorter aPTT is a risk
marker for incident and recurrent venous thromboembo-
lism (VTE) in the general population,4,5 and activated coag-
ulation is implicated in arterial thrombosis.6 An abnormal
PT may reflect liver damage, deficiencies in clotting factors
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Table 1. Description of Basic Study Participant Characteristics: Mean 5 SD or Percentage unless Otherwise Mentioned
ARIC MICROS LBC1936 LBC1921 CaPS MARTHA08 MARTHA10
Total na 9,240 1,334 925 471 891 649 392
Age, in years 54.3 5 5.7 44.7 5 16.7 69.6 5 0.84 79.1 5 0.57 56.9 5 4.3 44.4 5 14.3 48.3 5 16.1
Age range 45–64 9–94 68–71 78–81 48–67 1–90 7–85
% Female 52.9 57.2 49.4 59.6 0 75.8 63.3
BMI, in kg/m2 27.0 5 4.8 25.4 5 4.8 27.8 5 4.4 26.1 5 4.2 26.7 5 3.6 24.3 5 4.4 25.8 5 4.8
aPTT n 9,240 1,215 925 471 891 649 392
aPTT, in s 29.0 5 2.9 26.6 5 2.4 28.3 5 2.6 0.90 5 0.12b 33.0 5 2.8 31.3 5 3.4 31.6 5 3.2
Median aPTT 28.8 26.0 28.0 0.90b 32.7 31.0 31.4
IQR aPTT 27.1–30.7 25.0–28.0 26.0–30.0 0.82–0.99b 31.2–34.7 29.0–33.4 29.3–33.3
PT (INR) n NA 1,218 922 443 NA 612 374
PT (INR) NA 1.03 5 0.12 0.96 5 0.06 0.98 5 0.08 NA 99.8 5 13.5c 101.4 5 10.5c
Median PT (INR) NA 1.02 1.00 0.98 NA 99.0c 101.0c
IQR PT (INR) NA 0.98–1.06 0.90–1.00 0.93–1.03 NA 91.0–107.0c 94.2–108.0c
BMI, body mass index; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; IQR, interquartile range;
NA, not available.
aOverall n in the genome-wide association study of aPTT or INR after phenotype exclusions.
baPTT ratio.
cThe Quick value in %, which is in inverse relationship to INR.Family-based studies have yielded heritability estimates
of 0.43 to 0.83 for aPTT and 0.50 to 0.53 for PT, respec-
tively,7,8 and shared genetic correlations have been
observed between coagulation and thrombosis.9 To date,
one genome-wide association study (GWAS) of aPTT, based
on 542,050 genotyped SNPs in 1,477 participants of
the Lothian Birth Cohorts (LBC) of 1921 and 1936
(LBC1921, LBC1936),10 has been reported. In that study,
genome-wide significant associations were identified for
variants at F12 (MIM 610619), KNG1 (MIM 612358), and
HRG (MIM 142640).10 No GWAS has been reported to
date for PT. We report a community-based GWAS and
meta-analysis for aPTT and PT among participants of
European ancestry and assess the functional and clinical
relevance of identified loci.
The study population for aPTT comprised five commu-
nity-based cohorts and two samples of individuals with
VTE (Table 1). The community-based cohorts included
the Atherosclerosis Risk in Communities (ARIC) study
(final sample size n ¼ 9,240; USA),11 the Genetic Study of
Three Population Microisolates in South Tyrol (MICROS)
(n ¼ 1,215; Italy),12 LBC1921 (n ¼ 471; UK), LBC1936
(n ¼ 925; UK),13 and the Caerphilly Prospective Study
(CaPS) (n ¼ 891; UK).14 We studied individuals with VTE
from two independent samples of the Marseille Throm-
bosis Association (MARTHA; France) study: MARTHA08
(n ¼ 649) and MARTHA10 (n ¼ 392). Given that the
sample size for ARIC is much larger than that of the other
cohorts, the ARIC cohort was analyzed as the discovery
cohort and the others as replication cohorts.
PT was represented with the international normalized
ratio (INR), which standardizes the PT measure acrossThe Amstudies. Data for INR were available from MICROS
(n ¼ 1,218), LBC1921 (n ¼ 443), and LBC1936 (n ¼ 922)
(Table 1). All the three samples were analyzed as discovery
cohorts. Data from MARTHA08 (n ¼ 612) and MARTHA10
(n ¼ 374), which recorded only the Quick value (a PT ratio
of the coagulation time as a percentage of normal), were
analyzed as replications. Each study was approved by the
institutional review board of the corresponding institutes,
and participants gave informed consent.
aPTT and PT were measured in plasma with the use of
automated coagulometers and on the basis of standard
protocols specified in the individual studies. Tests were
conducted on the same day as blood collection or within
a few weeks (after freezing). aPTT in seconds (s) was avail-
able in all the cohorts except LBC1921, in which only
the aPTT ratio was available. The aPTT ratio was calculated
as the ratio of the subject’s aPTT to the reference value of
the laboratory and correlates nearly perfectly (R2 ¼ 0.95)
with aPTT values in LBC1936. INR was calculated as
(subject’s PT / mean normal PT)ISI, where ISI (international
sensitivity index) is a measure of the sensitivity of a partic-
ular PT reagent and is determined by the manufacturers.
Additional details on the coagulation measurements are
provided in Table S1 available online.
Each study independently performed assays for genome-
wide SNPs, quality control, and imputation on ~2.5
million autosomal SNPs identified in the HapMap II
sample with European ancestry (CEU [Utah residents
with ancestry from northern and western Europe]). DNA
samples were obtained from blood. The SNP arrays used
were Affymetrix 6.0 in ARIC, Illumina HumHap300v2
Infinium in MICROS, Illumina Human 610_Quadv1 inerican Journal of Human Genetics 91, 152–162, July 13, 2012 153
both LBC cohorts, Illumina Human 610_Quad in
MARTHA08, and Illumina Human 660W_Quad in
MARTHA10. Before imputation, SNPs were filtered on the
basis of sample and SNP call rates, Hardy-Weinberg equilib-
rium p values, and minor allele frequencies. Imputation
was performed with the use of MACH software15,16 in all
cohorts for estimation of the ‘‘allele dosage.’’ The accuracy
of imputation was reflected by the ratio of observed to ex-
pected variance (OEV) of the dosage statistic for each SNP.
In CaPS, de novo replication genotyping was performed
with a fluorescence-based competitive allele-specific PCR
system by KBioscience (Hoddesdon, UK). Genotyping
was successful in 22 out of 24 SNPs analyzed. Details are
provided in Table S1. In addition, the FV Leiden variant
(rs6025, MIMs 188055 and 612309) and the top SNP for
aPTT on chromosome 5 (rs2545801) were genotyped in
ARIC with an Illumina assay as part of the Candidate
gene Association Resource (CARe) project. The CARe data
for rs2545801 were analyzed for confirmation of the
GWAS results for this variant, which was imputed with
borderline precision in ARIC (OEV ¼ 0.3).
The association of aPTT or INR with genotyped or
imputed SNPswas testedwith the use of an additive genetic
model in accordance with a unified analysis plan. Outliers
or users of anticoagulants were excluded. Analysis was
conducted with linear regression models for studies of
unrelated individuals. A score test17 was used for testing
the genetic associationswhile accounting for familial corre-
lations in MICROS, which is a population study that
contains related individuals in extended families. All anal-
yseswere adjusted for age, sex, and other cohort-specific co-
variates and were performed with ProbABEL-GenABEL,18
Mach2QTL,15,16 or PLINK (Table S1).19
For aPTT, we performed an effective-sample-size-
weighted meta-analysis to combine p values and the direc-
tion of genetic effects from the replication (MICROS,
LBC1921, LBC1936, and CaPS) and discovery (ARIC)
cohorts. The p value-based approach was chosen because
of mixed aPTT and aPTT-ratio measurements across
cohorts. For INR, a fixed-effect, inverse-variance-weighted
meta-analysis approach was used to pool p values and
b coefficients from MICROS, LBC1921, and LBC1936.
The genomic-control correction was applied to each study
before the meta-analysis. The genomic-control inflation
factor l was around 1 (0.98–1.03) for both aPTT and INR
in all cohorts and in the meta-analyses. The meta-analyses
were conducted with the METAL package.20 The MARTHA
data were not pooled with the community-based cohorts
because of the possibility of different allele frequencies,21
linkage disequilibria (LD), and effect sizes in individuals
with VTE compared to the general population.
To examine the evidence for additional independent
signals in the presence of several significant associations
at a given locus, we performed additional conditional anal-
yses by adjusting for the top SNP observed in the region
until there were no significant residual signals detected.
LD statistics (r2) were estimated from combined data of154 The American Journal of Human Genetics 91, 152–162, July 13, 2the HapMap CEU and SeattleSNPs Programs for Genomic
Applications (PGA) European panel. Interaction was tested
between top SNPs of identified genes that have apparent
biological effects (KNG1, HRG, F11 [MIM 264900], and
F12) and was represented by a cross-product term between
dosages of two tested SNPs. Multiple testing was accounted
for by Bonferroni correction.
The aPTT GWAS findings are described in this and the
next six paragraphs. As shown in Figures S1 and S2 and
Table S2, 331 SNPs in ARIC from six regions exceeded
the genome-wide significance threshold of p < 5 3 108.
These included one SNP within F5 (MIM 612309), 107
SNPs in KNG1/HRG, 28 SNPs in CYP4V2 (MIM 608614) /
KLKB1 (MIM 229000) /F11, 110 SNPs in F12, four SNPs
in C6orf10, and 81 SNPs in ABO (MIM 110300). In the
meta-analysis pooling data from ARIC, MICROS,
LBC1936, and LBC1921 (Figures S3 and S4), a locus at
chromosome 15q25.3 (three SNPs, within ATP/GTP
binding protein-like 1, AGBL1) and another group of 29
SNPs within the F5 region emerged as statistically signifi-
cant. Associations of aPTT with lead SNPs at the seven
regions are presented in Table 2, Tables S3 and S4, and
Figures S5–S14.
More specifically, we confirmed independent associa-
tions with aPTT for rs710446 in KNG1, rs9898 in HRG,
and rs2731672 in F12, previously reported in the LBC
cohorts (r2 ¼ 0.93 between rs2731672 and our top SNP,
rs2545801).10 We also provided confirmation with
genome-wide significance for the previously reported
association of the ABO O blood group with aPTT in candi-
date-gene studies (top SNP: rs687621, r2 ¼ 0.67 with the O
functional variant).22,23
At the CYP4V2/KLKB1/F11 region, conditional analysis
in ARIC identified two sets of independent signals led
by two intronic variants in F11: rs2289252 (top SNP,
p ¼ 4.30 3 1030) and rs1593 (p ¼ 1.25 3 1017). These
two SNPs were in LD (r2 ¼ 0.09). After adjusting
for rs2289252, rs1593 was still associated with aPTT
(p ¼ 2.01 3 108). The first locus tagged by rs2289252
was identified as suggestive by a pathway-based approach
in the previously published GWAS for aPTT in LBC (top
SNP: rs4253399, p ¼ 1.8 3 105, r2 ¼ 0.79 with
rs2289252).10 The second locus led by rs1593 has not
previously been associated with aPTT, and it explains an
additional 0.33% of the variance in aPTT in ARIC beyond
what was explained by rs2289252 (Table S3).
The associations we identified for aPTTwith F5, C6orf10,
AGBL1, and a second independent locus in ABO have not
been previously reported for aPTT. The two loci in F5,
tagged by rs9332701 and rs6028, reside in coding regions
of F5 and are independent (r2 ¼ 0.015). In ARIC, adjust-
ment for rs9332701 only minimally influenced the signal
for rs6028 (p ¼ 3.84 3 107 and 4.27 3 106 before
and after adjustment, respectively). Heterozygotes for
rs9332701 have 25% lower plasma FV levels.24 The associ-
ations between aPTT and the two F5 variants in this study
were not due to their LD with the FV Leiden variant012
Table 2. Association Parameters for Top SNP Associations in Activated Partial Thromboplastin Time Genome-wide Association Study
Region Top SNP Position Gene/Var A1/A2/AF1 Imput
Beta/SE/Var% p Value/Direction
Comments
ARIC ARIC Replication MARTHAb
n ¼ 9,240 n ¼ 9,240 na ¼ 869–3,467 n ¼ 1,041
Achieving Genome-wide Significance in ARIC Alone
1q24.2 rs9332701c 167751391 F5/cns A/G/0.95 - 0.54/0.10/0.30 3.70 3 108/þ 0.62/þ NA present study
3q27 rs710446 c 187942621 KNG1/cns T/C/0.59 0.98–1.00 1.19/0.04/7.92 1.06 3 10185/ 2.72 3 1034/ 7.25 3 1022/ significant in PGWA
3q27 rs9898d 187873321 HRG/cns C/T/0.65 0.87–1.00 1.01/0.04/5.41 1.65 3 10116/ 5.03 3 106/ 2.58 3 1014/ significant in PGWA
4q35 rs2289252c 187444375 F11/intr C/T/0.59 0.86–0.97 0.48/0.04/1.31 4.30 3 1030/ 3.10 3 1016/ 3.83 3 105/e suggestive in PGWA
4q35 rs1593d 187432545 F11/intr A/T/0.87 0.86–0.90 0.54/0.06/0.77 1.25 3 1017/þ 0.005/þ 0.08/þ present study
5q33-qter rs2545801c 176773945 F12/pro C/T/0.84 0.30–0.89f 1.55/0.05/10.64g 4.13 3 1060/þh 3.49 3 1063/þ 6.20 3 1011/þ significant in PGWA
6p21.3 rs2050190 32447054 C6orf10/intr A/G/0.66 0.94–0.99 0.25/0.04/0.33 1.29 3 108/ 0.47/ 0.77/þ present study
9q34.1-.2 rs687621c 135126886 ABO/intr A/G/0.65 0.99–1.00 0.82/0.04/3.52 3.64 3 1081/ 7.25 3 1030/ 5.18 3 1010/ significant in PCGS
9q34.1-.2 rs8176704d,i 135125373 ABO/intr G/A/0.93 0.90–1.00 0.89/0.09/1.04 4.26 3 1024/þ 1.19 3 105/þ 0.002/þ present study
Achieving Genome-wide Significance in Meta-analysis of ARIC, MICROS, LBC1936, and LBC1921
1q24.2 rs6028d 167818306 F5/cs T/C/0.69 0.97–0.99 0.23/0.04/0.25 3.84 3 107/þ 0.001/þ 0.59/þ present study
15q25.3 rs2469184 84992981 AGBL1/intr G/A/0.55 0.99–1.00 0.16/0.04/0.15 8.19 3 105/þ 8.87 3 106/þ 0.35/þ present study
Beta, change in activated partial thromboplastin time (in s) per copy of the A2 allele (minor allele); Var%, percentage of variance explained; Direction (þ or ), direction of association associated with the minor allele;
Var, variant of the top SNP; A1, allele 1 (major allele); A2, allele 2 (minor allele); Imput, ratio of observed to expected variance as a measure of imputation quality (range presented here, 1 for genotyped SNPs); AF1, allele
frequency for A1; cns, coding nonsynonymous; NA, not available; PGWA, previously published genome-wide association study (GWAS) in Lothian Birth Cohorts (LBC); intr, intron; pro, promoter region; PCGS, previously
published candidate-gene studies; cs, coding synonymous.
an for replication: 869 is the n for rs9332701 that was only available in CaPS; n range for the other SNPs is 2,252–3,467.
bBased on meta-analysis of MARTHA08 and MARTHA10.
cTop SNP in that region if there is more than one independent SNP.
dSecond independent SNP, p value after adjusting for the top SNP of the region in ARIC: 9.95 3 1092 for rs9898, 2.01 3 108 for rs1593, and 4.27 3 106 for rs6028.
eResult for proxy rs925451 (r2 ¼ 0.81 with rs2289252).
f0.30 is the imputation quality score (OEV) in ARIC GWAS, OEV > 0.84 in the other cohorts.
gBased on the results of ARIC genotyped data from the Candidate gene Association Resource (CARe) project.
hp value < 10150 based on the ARIC genotype data from the CARe project.
iResults are after additionally adjusting for rs687621 in all cohorts.
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Figure 1. Cumulative Effect of the Lead
SNPs in KNG1, HRG, F11, F12, and ABO
on aPTT in ARIC
(A) Distribution of the genetic risk score
(range: 0.24–85.1), and relation of risk-
score categories to the mean aPTT (in s).
The histogram, with reference to the
y axis on the left, represents the number
of individuals in each risk-score category.
The black circles and error bars, with refer-
ence to the y axis on the right, indicate the
mean aPTT5 SD (in s).
(B) Predicted versus observed aPTT values.
The predicted aPTT values were calculated
on the basis of the regression of the
observed aPTT on the genetic risk score.(rs6025), because rs6025 was neither associated with aPTT
(p ¼ 0.54 for rs6025 in ARIC) nor correlated with the two
F5 variants (r2 < 0.005). The second independent locus
at the ABO region for aPTT included 20 significant SNPs
and emerged after additionally adjusting for the top SNP,
rs687621. The associations were led by rs4363269 and
rs8176704. Of the 20 significant signals, only rs8176704
is located within a gene (intronic to ABO, p ¼ 0.02 and
4.26 3 1024 before and after adjustment for rs68762,
respectively); it tags the ABO A2 variant (r2 ¼ 1), is in
weak LD with rs687621 (r2 ¼ 0.20), and explains an addi-
tional 1.0% of the variance in aPTT beyond what is
explained by rs687621.
Among the six genome-wide significant associations for
aPTT, identified in ARIC or the meta-analysis, the top
signal in F11 (rs2289252) and two independent ones in
the ABO region (rs687621 and rs8176704) were confirmed156 The American Journal of Human Genetics 91, 152–162, July 13, 2012in the replication samples (Table 2).
The associations for rs9332701 in
F5, rs1593 in F11, adjusted for
rs2289252, and rs2050190 in
C6orf10 were not significantly repli-
cated (Table 2), possibly due to
limited replication data. The two
associations that emerged only in
the meta-analysis (rs6028 in F5 and
rs2469184 in AGBL1) were consistent
across individual cohorts but require
additional replication (Table 2 and
Tables S2–S4). Of note, AGBL1 and
C6orf10 were not previously known
to affect coagulation.
In ARIC, we evaluated ten inter-
actions for aPTT among the top SNPs
in KNG1 (rs710446), HRG (rs9898),
F11 (rs2289252 and rs1593), and
F12 (rs2545801). On the basis of a
Bonferroni-adjusted alpha of 0.005,
the interactions for rs710446 3
rs9898, rs710446 3 rs1593, and
rs710446 3 rs2545801 were statisti-cally significant (Table S5). The interactions of rs710446
with rs9898 or with rs2545801 offset the marginal effects
of the aPTT-decreasing alleles (Figure S15).
In ARIC, the six loci in KNG1, HRG, F11, F12, and ABO,
which were replicated, together explained 28.7% of the
variation in aPTT, with 6.0% attributable to the genome-
wide significant associations in F11 (rs2289252) and ABO
(rs687621 and rs8176704) that were not reported in the
previous GWAS. A genetic risk score was created by
summing the product of the number of aPTT-increasing
alleles and the b coefficient from the meta-analysis for
the lead SNPs in the six loci, with the genetic risk score
rescaled to 100%. The genetic risk score showed an accu-
rate prediction of aPTT values (Figure 1). The Pearson corre-
lation was 0.53 (p < 0.0001), and the linear-regression
coefficient 5 SE was 1.00 5 0.016 between the observed
and predicted aPTT values. The mean aPTT ranged from
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The Am25.7 s in individuals in the lowest risk-score category (risk
score% 15, n ¼ 111) to 33.8 s in those in the highest risk-
score category (>72, n ¼ 159). Each 11-unit increase in the
genetic risk score corresponds to 1.21 s higher aPTT, which
corresponds to the mean aPTT difference between VTE
cases and controls.5
For the PT-related analyses, the INR GWAS results are
presented in Table 3, Table S6, and Figures S16–S19. Two
loci exceeded the genome-wide significance threshold of
p < 5 3 108: 24 SNPs near or within F7 (MIM 613878)
(top SNP: rs561241, near F7 50, p ¼ 3.71 3 1056) and 40
SNPs near or within EDEM2 (MIM 610302) and PROCR
(MIM 600646) (top SNP: rs2295888, intronic to EDEM2,
p ¼ 5.25 3 1013). Of note, rs867186, another top variant
(p ¼ 4.65 3 1012), is a coding nonsynonymous variant
in the endothelial protein C receptor gene (PROCR or
EPCR). The lead SNPs at the two loci together account for
10%–14% of the variation in INR. The associations were
significantly replicated in MARTHA (Table 3).
We next investigated pathways and networks by
entering the genome-wide-significant hits in the STRING
(Search Tool for the Retrieval of Interacting Genes/
Proteins) database.25 Two networks were identified, char-
acterizing mainly the intrinsic and extrinsic pathways
for aPTT and PT, respectively. Other members of the iden-
tified networks were tested further at the gene level with
the program VEGAS (Versatile Gene-based Association
Study), which performs gene-based tests after taking into
account of LD among SNPs.26 In this pathway- and gene-
based analysis (Figure S20), another gene, PLG (plasmin-
ogen, MIM 173350), emerged as a suggestive locus for
aPTT, and F5 emerged as a suggestive locus for INR
(p ¼ 0.0048 for PLG and 0.017 for F5, significant
threshold¼ 0.0033 for aPTT genes and 0.006 for INR genes
after Bonferroni correction). Plasmin, the activated form of
plasminogen, not only dissolves fibrin in blood clots, but
also mediates the activation of the contact coagulation
system.27
We next conducted gene expression association analysis
to focus on SNPs with p < 104 for aPTT (n ¼ 1,124 SNPs)
or INR (n ¼ 340) from the meta-analysis. These SNPs were
searched against a collected database of expression quanti-
tative trait locus (eQTL) results on the basis of blood-
derived and related organ tissues, including CD4þ
lymphocytes,28 monocytes,29 adipose and blood
samples,30,31 liver,31–33 and brain tissues (V.E., unpub-
lished data). eQTL results were judged significant based
on p < 4 3 105 and 1 3 104 for aPTT and INR, respec-
tively, after accounting for multiple testing. Table 4 pres-
ents the smallest gene expression association p values for
each relevant tissue at the corresponding GWAS regions.
When the top GWAS SNPs were not available in the expres-
sion databases, expression SNPs (eSNPs) that correlated
with the top GWAS SNPs at r2 R 0.8 were considered as
strongly supporting eSNPs. As shown in Table 4 and Tables
S7 and S8, five of the GWAS loci (F5, F12, ABO, F7, and
EDEM2/PROCR) contained at least one strongly supportingerican Journal of Human Genetics 91, 152–162, July 13, 2012 157
Table 4. Selected Top Gene Expression Associations Related to Loci for aPTT or INR
eSNP Region Tissue Genes Nearbya
p Value
Expression/n Transcript
p Value
GWAS
r2 to Top
GWAS SNP
Top
GWAS SNP
aPTT
rs1894702 1q24.2 CD4þ
lymphocytes28
F5;SELP 7.59 3 1017/200 F5 8.11 3 109 0.92 rs6028
rs7542088 monocytes29 F5;SELP 4.74 3 1014/1,490 F5 9.37 3 109 0.96 rs6028
rs3917854 whole-blood30 F5;SELP 3.90 3 1050/1,469 F5 3.05 3 108 0.96 rs6028
rs2731672 5q33 liver31 F12;GRK6; SLC34A1;
PRR7; RGS14;DBN1
6.13 3 1053/607 F12 2.43 3 1034 0.93 rs2545801
liver32 1.16 3 1023/472 F12
liver33 <1.00 3 1016/206 F12
liver33 1.52 3 106/60 F12
rs505922 9q34.2 CD4þ
lymphocytes28
ABO;SURF6;MED22 2.69 3 105/200 ABO 1.04 3 1099 0.97 rs687621
rs2437792 15q25.3 CBb AGBL1 5.34 3 105/496 AA620749c 2.66 3 107 0.87 rs2469184
INR
rs7981123d 13q34 liver33 F7; MCF2L; F10 2.78 3 1010/266 F7 7.24 3 1056 0.82 rs561241
liver33 4.88 3 1010/206 F7
liver33 9.62 3 103/60 F7
rs488703 omental adipose31 F7; MCF2L; F10 4.77 3 1010/848 F7 1.23 3 1055 0.88 rs561241
rs10665 subcutaneous
adipose31
F7; MCF2L; F10 2.07 3 106/701 F7 6.45 3 1053 0.92 rs561241
DLPFCb 1.82 3 107/583 F7
VCb 1.33 3 107/409 F7
rs11906318 20q11.2 liver31 EDEM2;PROCR 3.20 3 1020/607 PROCR 7.27 3 1013 1.00 rs2295888
rs11907010 omental adipose31 EDEM2;PROCR 5.62 3 1018/848 PROCR 1.03 3 1012 1.00 rs2295888
rs8119351 whole-blood30 EDEM2;PROCR 2.60 3 1046/1,469 EIF6 1.19 3 1012 1.00 rs2295888
rs6060244 monocytes29 EDEM2;TRPC4AP 5.26 3 1024/1,490 EIF6 7.02 3 1012 0.82 rs2295888
eSNP, expression SNP; GWAS, genome-wide association study; aPTT, activated partial thromboplastin time; INR, international normalized ratio; CB, cerebellum;
DLPFC, dorsolateral prefrontal cortex; VC, visual cortex; EIF6, ITGB4BP.
a‘‘Nearby’’ is defined by 60,000 bp from gene boundaries; the genes are ordered by distance to the eSNP; the gene in which the top eSNP is located is in bold font
bV.E., unpublished data.
cAA620749 maps to unspliced and spliced expressed sequence tags that are ~25–60 kb 50 of AGBL1.
drs7981123 is positioned at350 nt from the F7 transcription start site and is within regulatory elements based on alignment of ENCODE histone, DNase I hyper-
sensitivity, and ChIP-sequencing data; in dbSNP, rs7981123 has merged into rs510335.eSNP in at least one tissue, with strong support for F5, F12,
F7, PROCR, and EIF6 (eukaryotic initiation translation
factor 6, MIM 602912) as important genes.
We next assessed the clinical relevance of the top ten
independent SNPs associated with aPTT or INR using the
CAD GWAS data from the Coronary Artery Disease
Genome-wide Replication and Meta-analysis (CARDIo-
GRAM) study, which comprises 22,233 cases of CAD and
64,762 controls of European ancestry.34,35 The threshold
for statistical significance was set at p < 0.005 for aPTT
loci and p < 0.025 for INR after adjustment for multiple
testing. As shown in Table S9, CADwas strongly and signif-
icantly associated with the proxy SNP for the O group
(rs687621: odds ratio [OR] [95% confidence interval
(CI)]¼ 1.06 [1.03–1.10] per one copy increase in the minor158 The American Journal of Human Genetics 91, 152–162, July 13, 2allele, p ¼ 4.0 3 105) and with the top variants at the
PROCR/EDEM2 locus (rs867186: OR [95% CI] ¼ 0.93
[0.89–0.97], p¼ 0.002). The ABO-O association was consis-
tent with previously published results in CARDIoGRAM.34
These results highlight that the coagulation pathways
represent major molecular mechanisms through which
some of the recently identified CAD risk alleles34 may be
operating.
In this and the next four paragraphs, we offer a discus-
sion of our results. This study provides evidence confirm-
ing the contributions of genetic factors in the CYP4V2/
KLKB1/F11 region to normal variation of aPTT. Multiple
SNPs in CYP4V2, KLKB1, and F11 have been indepen-
dently associated with deep vein thrombosis (DVT)36,37,
and the first top SNP for aPTT, rs2289252, was confirmed012
as a strong DVT variant.37,38 Another SNP, rs2036914, was
associated with DVT independent of rs2289252.37 We
noted that rs1593, the second top independent variant
for aPTT, associated more strongly with rs2036914 than
with rs2289252 (r2¼ 0.17 versus 0.09). These observations,
combined with the GWAS data presented in this study,
suggest that more than one locus at this region influences
coagulation function and the risk of DVT.
We not only confirmed the previously reported positive
association between the ABO-O blood group and aPTT,22,23
but also identified a second independent locus represented
by rs8176704, a perfect tag for the A2 group. The genome-
wide significant associations for the second locus emerged
after adjustment for the top SNP, rs687621, a tag for the
O group. The adjustment substantially improved the signal
for rs8176704, due to the existence of negative confound-
ing between the two variants. There is a modest LD
between the two variants (r2 ¼ 0.2), with the minor allele
of rs8176704 residing on the same ancestral haplotype
block as the minor allele of rs687621 (Figure S21). These
two alleles showed opposite directions of association
with aPTT and, therefore, counteracted the marginal asso-
ciation with each other when the adjustment was not
considered. ABO encodes a glycosyltransferase with three
main alleles: A, B, and O. The A and B glycosyltransferases
transfer N-acetyl-D-galactosamine and D-galactose to
H antigen, respectively, whereas the O glycosyltransferase
does not possess any enzymatic function.39 The A2
subgroup is characterized by a single-base deletion near
the carboxyl terminal, resulting in a protein with little or
no A-type transferase activity.40 The influence of the ABO
blood group on coagulation function has been postulated
to be mediated through plasma clearance of von Wille-
brand factor (vWF), i.e., quicker clearance of vWF in
O and A2 groups.41 Both the O and A2 groups are associ-
ated with reduced risk of VTE,42 indicating that both loci
for aPTT are clinically relevant.
The significant genetic interactions of KNG1 with HRG
and F12 have not been previously reported. In the intrinsic
or contact coagulation pathway, high-molecular-weight
kininogen (HMWK), encoded by KNG1, acts as a cofactor
for activationof kallikrein and FXI and FXII.43HRG encodes
a histidine-rich glycoprotein, which is located in the
plasma and platelets. The physiological function of HRG
is not well understood, but it is known to interact with
heparin, thrombospondin, and plasminogen.44 Human
cases with congenital deficiency of HRGmanifested throm-
bophilia (MIM613116).45,46Mice deficient inHRG showed
enhanced blood coagulation and fibrinolysis.47 KNG1 and
HRG are located immediately adjacent to each other on
chromosome 3. There is a high degree of structural simi-
larity between them,48 indicating the possibility of shared
function.48 The interaction detected in our study suggests
that HRG may interact with the same receptors as HMWK
in the intrinsic or contact coagulation pathway.
SNPs in F7 were a major contributor to variation of the
functional index of the extrinsic pathway, explainingThe Am8.6%–12.2% of variance in PT (INR). One of the top vari-
ants at this region, rs6046, results in an arginine-glutamine
(R353Q) substitution. It was associated with FVII antigen
and activity in a published GWAS.49 Interestingly, this
variant explains more variance in INR than in FVII antigen
and activity,49 suggesting that additional mechanisms,
such as the interaction of FVII with other coagulation
factors in the extrinsic pathway,may underlie the observed
genetic associations.
Positive associations of the minor allele of rs867186
(PROCR S219G) with circulating levels of protein C and
soluble EPCR (sEPCR) have been reported consistently in
candidate-gene50–52 and GWAS studies.53 This variant
explained 10%–13% of variation in protein C and 75%
in sEPCR.51,53 The association between PT and the variants
at this locus may be mediated through the interaction of
EPCR with FVII, as the binding of activated FVII to EPCR
has been observed.54,55 Our study has extended the previ-
ously reported genetic associations with FVII antigen and
activity49,52 to the global functional assay of the extrinsic
pathway. The association of rs867186 with CAD has been
investigated in two small-sized candidate-gene studies,
which observed null or opposite directions of association
compared to ours.50,51 Our study, based on data from
a larger CAD consortium, has greater statistical power.
The minor allele that was associated with decreased risk
of CAD in our study was also associated with increased
protein C levels,51,53 consistent with the hypothesis of
a protective effect of the protein C-activated protein C
pathway on CAD risk.56 Interestingly, the rs867186/
rs2295888 locus also showed strong associations with the
expression of the ITGB4BP/EIF6, which is involved in regu-
lation of translation in response to extracellular signals.57
As such, the gene expression data may point to a novel
mechanism by which this locus influences coagulation
and CAD risk.
In summary, we identified and replicated genome-wide
significant associations at KNG1, HRG, F11, F12, and ABO
for aPTT and at the F7 and PROCR/EDEM2 regions for
PT. The loci identified in previous studies and in this
study together explained a substantial proportion of the
variance in aPTT and PT, which are important clinical
tests. The underlying causal variants in KNG1, HRG, and
F12 may interact with each other in influencing coagula-
tion and aPTT levels. This GWAS, together with gene
expression and clinical CAD data, improves our under-
standing of the role of biological mechanisms in the
regulation of hemostasis and may offer new approaches
to the prevention and treatment of arterial and venous
thrombosis.Supplemental Data
Supplemental Data include 21 figures, nine tables, acknowledg-
ments and funding information for each individual study, disclo-
sures, and a complete list of the CARDIoGRAM members and can
be found with this article online at http://www.cell.com/AJHG/.erican Journal of Human Genetics 91, 152–162, July 13, 2012 159
Acknowledgments
We warmly thank all staff and participants. The individual studies
were supported by the National Institutes of Health (NIH) or other
funding sources. W.T. is partially supported by NIH grant R01-
HL095603. We would like to thank the University of Minnesota
Supercomputing Institute for use of the Blade and Calhoun super-
computers. Additional acknowledgments for each study and
conflict-of-interest disclosures are listed in the Supplemental Data.
Received: September 5, 2011
Revised: April 10, 2012
Accepted: May 5, 2012
Published online: June 14, 2012Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
GeneCards, http://www.genecards.org/
International HapMap Project, http://www.hapmap.org
KBioscience genotyping services, http://www.kbioscience.co.uk/
MACH 1.0 and Mach2QTL, http://www.sph.umich.edu/csg/
abecasis/MACH/
METAL, http://www.sph.umich.edu/csg/abecasis/metal
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink
ProbABEL and GenABEL, http://www.genabel.org/packages
SeattleSNPs, http://pga.gs.washington.edu/
STRING database, http://string-db.org/
UCSC Human Genome Browser Gateway, http://genome.ucsc.
edu/cgi-bin/hgGateway
VEGAS, http://gump.qimr.edu.au/VEGAS/References
1. White, G.C., 2nd. (2003). The partial thromboplastin time:
defining an era in coagulation. J. Thromb. Haemost. 1,
2267–2270.
2. Kitchen, S., McCraw, A., and Echenagucia, M. (2010).
Diagnosis of Hemophilia and Other Bleeding Disorders: A
Laboratory Manual, 2nd ed. (Montreal: World Federation of
Hemophilia (WFH)).
3. Jacobs, D.S. (2001). Laboratory test handbook (Hudson, Ohio:
Lexi-Comp).
4. Hron, G., Eichinger, S., Weltermann, A., Quehenberger, P.,
Halbmayer, W.M., and Kyrle, P.A. (2006). Prediction of recur-
rent venous thromboembolism by the activated partial throm-
boplastin time. J. Thromb. Haemost. 4, 752–756.
5. Zakai, N.A., Ohira, T., White, R., Folsom, A.R., and Cush-
man, M. (2008). Activated partial thromboplastin time and
risk of future venous thromboembolism. Am. J. Med. 121,
231–238.
6. Owens, A.P., 3rd, and Mackman, N. (2010). Tissue factor and
thrombosis: The clot starts here. Thromb. Haemost. 104,
432–439.
7. Souto, J.C., Almasy, L., Borrell, M., Garı´, M., Martı´nez, E.,
Mateo, J., Stone, W.H., Blangero, J., and Fontcuberta, J.
(2000). Genetic determinants of hemostasis phenotypes in
Spanish families. Circulation 101, 1546–1551.160 The American Journal of Human Genetics 91, 152–162, July 13, 28. Warren, D.M., Soria, J.M., Souto, J.C., Comuzzie, A., Fontcu-
berta, J., Blangero, J., MacCluer, J.W., and Almasy, L. (2005).
Heritability of hemostasis phenotypes and their correlation
with type 2 diabetes status in Mexican Americans. Hum.
Biol. 77, 1–15.
9. Souto, J.C., Almasy, L., Borrell, M., Blanco-Vaca, F., Mateo, J.,
Soria, J.M., Coll, I., Felices, R., Stone, W., Fontcuberta, J., and
Blangero, J. (2000). Genetic susceptibility to thrombosis and
its relationship to physiological risk factors: the GAIT study.
Genetic Analysis of Idiopathic Thrombophilia. Am. J. Hum.
Genet. 67, 1452–1459.
10. Houlihan, L.M., Davies, G., Tenesa, A., Harris, S.E., Luciano,
M., Gow, A.J., McGhee, K.A., Liewald, D.C., Porteous, D.J.,
Starr, J.M., et al. (2010). Common variants of large effect in
F12, KNG1, and HRG are associated with activated partial
thromboplastin time. Am. J. Hum. Genet. 86, 626–631.
11. The Atherosclerosis Risk in Communities (ARIC) Study: design
and objectives. The ARIC investigators. Am. J. Epidemiol. 129,
687–702.
12. Pattaro, C., Marroni, F., Riegler, A., Mascalzoni, D., Pichler, I.,
Volpato, C.B., Dal Cero, U., De Grandi, A., Egger, C., Eisendle,
A., et al. (2007). The genetic study of three population micro-
isolates in South Tyrol (MICROS): study design and epidemio-
logical perspectives. BMC Med. Genet. 8, 29.
13. Deary, I.J., Gow, A.J., Taylor, M.D., Corley, J., Brett, C., Wilson,
V., Campbell, H., Whalley, L.J., Visscher, P.M., Porteous, D.J.,
and Starr, J.M. (2007). The Lothian Birth Cohort 1936: a study
to examine influences on cognitive ageing from age 11 to
age 70 and beyond. BMC Geriatr. 7, 28.
14. Yarnell, J.W., Sweetnam, P.M., Rumley, A., and Lowe, G.D.
(2001). Lifestyle factors and coagulation activation markers:
the Caerphilly Study. Blood Coagul. Fibrinolysis 12, 721–728.
15. Li, Y., Willer, C., Sanna, S., and Abecasis, G. (2009). Genotype
imputation. Annu. Rev. Genomics Hum. Genet. 10, 387–406.
16. Li, Y., Willer, C.J., Ding, J., Scheet, P., and Abecasis, G.R.
(2010). MaCH: using sequence and genotype data to estimate
haplotypes and unobserved genotypes. Genet. Epidemiol. 34,
816–834.
17. Chen, W.M., and Abecasis, G.R. (2007). Family-based associa-
tion tests for genomewide association scans. Am. J. Hum.
Genet. 81, 913–926.
18. Aulchenko, Y.S., Ripke, S., Isaacs, A., and van Duijn, C.M.
(2007). GenABEL: an R library for genome-wide association
analysis. Bioinformatics 23, 1294–1296.
19. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
20. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and
efficient meta-analysis of genomewide association scans.
Bioinformatics 26, 2190–2191.
21. Morange, P.E., Oudot-Mellakh, T., Cohen, W., Germain, M.,
Saut, N., Antoni, G., Alessi, M.C., Bertrand, M., Dupuy,
A.M., Letenneur, L., et al. (2011). KNG1 Ile581Thr and suscep-
tibility to venous thrombosis. Blood 117, 3692–3694.
22. Fourel, V., Gabastou, J.M., Desroys du Roure, F., Ehrhardt, N.,
and Robert, A. (1993). Influence of age, sex and ABO blood
group on activated partial thromboplastin time. Haemostasis
23, 321–326.
23. Souto, J.C., Almasy, L., Mun˜iz-Diaz, E., Soria, J.M., Borrell, M.,
Baye´n, L., Mateo, J., Madoz, P., Stone, W., Blangero, J., and012
Fontcuberta, J. (2000). Functional effects of the ABO locus
polymorphism on plasma levels of von Willebrand factor,
factor VIII, and activated partial thromboplastin time. Arte-
rioscler. Thromb. Vasc. Biol. 20, 2024–2028.
24. Scanavini, D., Girelli, D., Lunghi, B., Martinelli, N., Legnani,
C., Pinotti, M., Palareti, G., and Bernardi, F. (2004). Modula-
tion of factor V levels in plasma by polymorphisms in the
C2 domain. Arterioscler. Thromb. Vasc. Biol. 24, 200–206.
25. Jensen, L.J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C.,
Muller, J., Doerks, T., Julien, P., Roth, A., Simonovic, M.,
et al. (2009). STRING 8—a global view on proteins and their
functional interactions in 630 organisms. Nucleic Acids Res.
37 (Database issue), D412–D416.
26. Liu, J.Z., McRae, A.F., Nyholt, D.R., Medland, S.E., Wray, N.R.,
Brown, K.M., Hayward, N.K., Montgomery, G.W., Visscher,
P.M., Martin, N.G., and Macgregor, S.; AMFS Investigators.
(2010). A versatile gene-based test for genome-wide associa-
tion studies. Am. J. Hum. Genet. 87, 139–145.
27. Ewald, G.A., and Eisenberg, P.R. (1995). Plasmin-mediated
activation of contact system in response to pharmacological
thrombolysis. Circulation 91, 28–36.
28. Murphy, A., Chu, J.H., Xu, M., Carey, V.J., Lazarus, R., Liu, A.,
Szefler, S.J., Strunk, R., Demuth, K., Castro, M., et al. (2010).
Mapping of numerous disease-associated expression polymor-
phisms in primary peripheral blood CD4þ lymphocytes.
Hum. Mol. Genet. 19, 4745–4757.
29. Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Cas-
tagne, R., Maouche, S., Germain, M., Lackner, K., Rossmann,
H., et al. (2010). Genetics and beyond—the transcriptome of
human monocytes and disease susceptibility. PLoS ONE 5,
e10693.
30. Fehrmann, R.S., Jansen, R.C., Veldink, J.H., Westra, H.J.,
Arends, D., Bonder, M.J., Fu, J., Deelen, P., Groen, H.J., Smo-
lonska, A., et al. (2011). Trans-eQTLs reveal that independent
genetic variants associated with a complex phenotype
converge on intermediate genes, with a major role for the
HLA. PLoS Genet. 7, e1002197.
31. Greenawalt, D.M., Dobrin, R., Chudin, E., Hatoum, I.J., Suver,
C., Beaulaurier, J., Zhang, B., Castro, V., Zhu, J., Sieberts, S.K.,
et al. (2011). A survey of the genetics of stomach, liver, and
adipose gene expression from a morbidly obese cohort.
Genome Res. 21, 1008–1016.
32. Schadt, E.E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum,
P.Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., et al.
(2008). Mapping the genetic architecture of gene expression
in human liver. PLoS Biol. 6, e107.
33. Innocenti, F., Cooper, G.M., Stanaway, I.B., Gamazon, E.R.,
Smith, J.D., Mirkov, S., Ramirez, J., Liu, W., Lin, Y.S., Moloney,
C., et al. (2011). Identification, replication, and functional
fine-mapping of expression quantitative trait loci in primary
human liver tissue. PLoS Genet. 7, e1002078.
34. Schunkert, H., Ko¨nig, I.R., Kathiresan, S., Reilly, M.P., Assimes,
T.L., Holm, H., Preuss, M., Stewart, A.F., Barbalic, M., Gieger,
C., et al; Cardiogenics; CARDIoGRAM Consortium. (2011).
Large-scale association analysis identifies 13 new suscepti-
bility loci for coronary artery disease. Nat. Genet. 43, 333–338.
35. Preuss, M., Ko¨nig, I.R., Thompson, J.R., Erdmann, J., Absher,
D., Assimes, T.L., Blankenberg, S., Boerwinkle, E., Chen, L.,
Cupples, L.A., et al; CARDIoGRAM Consortium. (2010).
Design of the Coronary ARtery DIsease Genome-Wide Repli-
cation And Meta-Analysis (CARDIoGRAM) Study: A
Genome-wide association meta-analysis involving moreThe Amthan 22 000 cases and 60 000 controls. Circ Cardiovasc Genet.
3, 475–483.
36. Bezemer, I.D., Bare, L.A., Doggen, C.J., Arellano, A.R., Tong,
C., Rowland, C.M., Catanese, J., Young, B.A., Reitsma, P.H.,
Devlin, J.J., and Rosendaal, F.R. (2008). Gene variants associ-
ated with deep vein thrombosis. JAMA 299, 1306–1314.
37. Li, Y., Bezemer, I.D., Rowland, C.M., Tong, C.H., Arellano,
A.R., Catanese, J.J., Devlin, J.J., Reitsma, P.H., Bare, L.A., and
Rosendaal, F.R. (2009). Genetic variants associated with deep
vein thrombosis: the F11 locus. J. Thromb. Haemost. 7,
1802–1808.
38. Smith, N.L., Hindorff, L.A., Heckbert, S.R., Lemaitre, R.N.,
Marciante, K.D., Rice, K., Lumley, T., Bis, J.C., Wiggins, K.L.,
Rosendaal, F.R., and Psaty, B.M. (2007). Association of genetic
variations with nonfatal venous thrombosis in postmeno-
pausal women. JAMA 297, 489–498.
39. Greenwell, P. (1997). Blood group antigens: molecules seeking
a function? Glycoconj. J. 14, 159–173.
40. Hosoi, E. (2008). Biological and clinical aspects of ABO blood
group system. J. Med. Invest. 55, 174–182.
41. Morelli, V.M., de Visser, M.C., van Tilburg, N.H., Vos, H.L., Ei-
kenboom, J.C., Rosendaal, F.R., and Bertina, R.M. (2007). ABO
blood group genotypes, plasma von Willebrand factor levels
and loading of von Willebrand factor with A and B antigens.
Thromb. Haemost. 97, 534–541.
42. Tre´goue¨t, D.A., Heath, S., Saut, N., Biron-Andreani, C.,
Schved, J.F., Pernod, G., Galan, P., Drouet, L., Zelenika, D., Ju-
han-Vague, I., et al. (2009). Common susceptibility alleles are
unlikely to contribute as strongly as the FV and ABO loci to
VTE risk: results from a GWAS approach. Blood 113, 5298–
5303.
43. Sainz, I.M., Pixley, R.A., and Colman, R.W. (2007). Fifty years
of research on the plasma kallikrein-kinin system: from
protein structure and function to cell biology and in-vivo
pathophysiology. Thromb. Haemost. 98, 77–83.
44. Jones, A.L., Hulett, M.D., and Parish, C.R. (2005). Histidine-
rich glycoprotein: A novel adaptor protein in plasma that
modulates the immune, vascular and coagulation systems.
Immunol. Cell Biol. 83, 106–118.
45. Shigekiyo, T., Yoshida, H., Kanagawa, Y., Satoh, K., Wakabaya-
shi, S., Matsumoto, T., and Koide, T. (2000). Histidine-rich
glycoprotein (HRG) Tokushima 2: novel HRG deficiency,
molecular and cellular characterization. Thromb. Haemost.
84, 675–679.
46. Shigekiyo, T., Yoshida, H., Matsumoto, K., Azuma, H., Waka-
bayashi, S., Saito, S., Fujikawa, K., and Koide, T. (1998). HRG
Tokushima: molecular and cellular characterization of histi-
dine-rich glycoprotein (HRG) deficiency. Blood 91, 128–133.
47. Tsuchida-Straeten, N., Ensslen, S., Scha¨fer, C., Wo¨ltje, M., De-
necke, B., Moser, M., Gra¨ber, S., Wakabayashi, S., Koide, T.,
and Jahnen-Dechent, W. (2005). Enhanced blood coagulation
and fibrinolysis in mice lacking histidine-rich glycoprotein
(HRG). J. Thromb. Haemost. 3, 865–872.
48. Lee, C., Bongcam-Rudloff, E., Sollner, C., Jahnen-Dechent,W.,
and Claesson-Welsh, L. (2009). Type 3 cystatins; fetuins, kini-
nogen and histidine-rich glycoprotein. Front. Biosci. 14,
2911–2922.
49. Smith, N.L., Chen,M.H., Dehghan, A., Strachan, D.P., Basu, S.,
Soranzo, N., Hayward, C., Rudan, I., Sabater-Lleal, M., Bis, J.C.,
et al; Wellcome Trust Case Control Consortium. (2010). Novel
associations of multiple genetic loci with plasma levels of
factor VII, factor VIII, and von Willebrand factor: Theerican Journal of Human Genetics 91, 152–162, July 13, 2012 161
CHARGE (Cohorts for Heart and Aging Research in Genome
Epidemiology) Consortium. Circulation 121, 1382–1392.
50. Ireland, H., Konstantoulas, C.J., Cooper, J.A., Hawe, E.,
Humphries, S.E., Mather, H., Goodall, A.H., Hogwood, J.,
Juhan-Vague, I., Yudkin, J.S., et al. (2005). EPCR Ser219Gly:
elevated sEPCR, prothrombin F1þ2, risk for coronary heart
disease, and increased sEPCR shedding in vitro. Atheroscle-
rosis 183, 283–292.
51. Reiner, A.P., Carty, C.L., Jenny, N.S., Nievergelt, C., Cushman,
M., Stearns-Kurosawa, D.J., Kurosawa, S., Kuller, L.H., and
Lange, L.A. (2008). PROC, PROCR and PROS1 polymor-
phisms, plasma anticoagulant phenotypes, and risk of cardio-
vascular disease and mortality in older adults: the Cardiovas-
cular Health Study. J. Thromb. Haemost. 6, 1625–1632.
52. Ireland, H.A., Cooper, J.A., Drenos, F., Acharya, J., Mitchell,
J.P., Bauer, K.A., Morrissey, J.H., Esnouf, M.P., and Humphries,
S.E. (2009). FVII, FVIIa, and downstream markers of extrinsic
pathway activation differ by EPCR Ser219Gly variant in
healthy men. Arterioscler. Thromb. Vasc. Biol. 29, 1968–1974.162 The American Journal of Human Genetics 91, 152–162, July 13, 253. Tang, W., Basu, S., Kong, X., Pankow, J.S., Aleksic, N., Tan, A.,
Cushman, M., Boerwinkle, E., and Folsom, A.R. (2010).
Genome-wide association study identifies novel loci for
plasma levels of protein C: the ARIC study. Blood 116,
5032–5036.
54. Ghosh, S., Pendurthi, U.R., Steinoe, A., Esmon, C.T., and Rao,
L.V. (2007). Endothelial cell proteinC receptor acts as a cellular
receptor for factor VIIa on endothelium. J. Biol. Chem. 282,
11849–11857.
55. Lo´pez-Sagaseta, J., Montes, R., Puy, C., Dı´ez, N., Fukudome, K.,
and Hermida, J. (2007). Binding of factor VIIa to the endothe-
lial cell protein C receptor reduces its coagulant activity.
J. Thromb. Haemost. 5, 1817–1824.
56. Jackson, C.J., and Xue, M. (2008). Activated protein C—an
anticoagulant that does more than stop clots. Int. J. Biochem.
Cell Biol. 40, 2692–2697.
57. Gandin, V., Miluzio, A., Barbieri, A.M., Beugnet, A., Kiyokawa,
H., Marchisio, P.C., and Biffo, S. (2008). Eukaryotic initiation
factor 6 is rate-limiting in translation, growth and transforma-
tion. Nature 455, 684–688.012
